GeoVax Labs Inc. Common Stock (GOVX)

FairStock Score: 68/100 — STEADY

Key Financials

AI Analysis

AI-generated, general educational analysis — not personal investment advice.

I approach this as a Graham-style balance-sheet investor, and GeoVax is a clinical-stage biotech with no steady earnings power. In fiscal year 2025, the year ended 2025-12-31, it reported revenue of $2.5 million and a net loss of $21.5 million; in fiscal year 2024, the year ended 2024-12-31, revenue was $4.0 million and net loss was $25.0 million; in fiscal year 2023, the year ended 2023-12-31, net loss was $26.0 million. Recent filings show continued red ink: fiscal Q2 2026, the quarter ended 2026-06-30, had a net loss of $4.4 million and EPS of -$0.97, while fiscal Q1 2026, the quarter ended 2026-03-31, lost $5.3 million. Trailing free cash flow was -$18.4 million, per FairStock, against a $2.0 million market cap at the 2026-10-13 close; that is a -937.1% FCF yield. The capital structure shows D/E of 0.18, but FairStock also calculates ROE of -891.59%, ROCE of -256.80%, Altman Z of -51.28, and Piotroski F-Score of 4/9, all signs of fragility. The company has proprietary vaccine platforms and clinical candidates, including GEO-CM04S1 in Phase 2 and Gedeptin in Phase 1/2, but no approved product means no pricing power or moat. At the 2026-10-13 close of $0.27, FairStock's P/B is 1.11 and P/E is -0.05; those are not a margin of safety. The loss in each of the last four years and lack of a Lynch category tell me this is a speculative science story, not a predictable business. I would need evidence of durable revenue and self-funding before treating it as investment grade.

In plain English: GeoVax Labs is a small research-stage biotech trying to develop vaccines and cancer treatments, with only 19 employees and no steady product revenue. The business is not yet profitable and has lost money in each of the last four years. At $0.27 on 2026-10-13, the whole company is valued at about $2.0 million; based on current losses and cash use, the price looks speculative rather than supported by today's business.

The full AI analysis, bull and bear case and key monitorables are in FairStock Pro.

Data as of 2026-10-13 close · note generated 2026-10-15 · model deepseek-flash

Sources (SEC EDGAR): fiscal Q2 2026 10-Q (period ended 2026-06-30) · fiscal Q1 2026 10-Q (period ended 2026-03-31) · fiscal Q3 2025 10-Q (period ended 2025-09-30) · fiscal Q2 2025 10-Q (period ended 2025-06-30) · FY2025 10-K (period ended 2025-12-31) · FY2024 10-K (period ended 2024-12-31) · FY2023 10-K (period ended 2023-12-31)

Fundamentals from company filings and market-data providers; prices are end-of-day, not real-time. AI-generated analysis is general and educational — not personal investment advice. Scoring methodology · Score test · Disclaimer